635702-60-2

Basic information

• Product Name: 2,3-dimethyl-2H-indazol-6-amine hydrochloride
• Synonyms: 2,3-dimethyl-2H-indazol-6-amine hydrochloride;2,3-Dimethyl-2H-indazol-6-amine monohydrochloride;2,3-Dimethyl-6-amino-2H-indazole hydrochloride;2H-Indazol-6-aMine,2,3-diMethyl-, hydrochloride (1:1);3-Methyl-6-nitro-1H-indazole hydrochloride;2H-Indazol-6-aMine,2,3-diMethyl-, hydrochloride;6-Amino-2,3-dimethyl-2H-indazole Hydrochloride;2,3-Dimethyl-2H-indazol-6-amine hydrochloride 2,3-Dimethyl-2H-indazol-6-amine monohydrochloride
• CAS NO: 635702-60-2
• Molecular Formula: C₉H₁₁N₃*ClH
• Molecular Weight: 197.66468
• EINECS: -0
• Mol File: 635702-60-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: 2,3-dimethyl-2H-indazol-6-amine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dimethyl-2H-indazol-6-amine hydrochloride(635702-60-2)
• EPA Substance Registry System: 2,3-dimethyl-2H-indazol-6-amine hydrochloride(635702-60-2)

Safety Data

• Hazardous Substances Data: 635702-60-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H11N3.ClH/c1-6-8-4-3-7(10)5-9(8)11-12(6)2;/h3-5H,10H2,1-2H3;1H

Upstream product

• 444731-73-1 2,3?dimethyl?6?nitro?2H?indazole 
• 6494-19-5 3-methyl-6-nitro-1H-indazole 
• 635702-59-9 3-methyl-6-nitro-1H-indazole sulfate 
• 20191-74-6 2-ethyl-5-nitroaniline 

Downstream Products

• 444731-74-2 N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine 
• 1226499-98-4 N2,N4-bis(2,3-dimethyl-2H-indazol-6-yl)-pyrimidine-2,4-diamine 

Relevant articles and documents

Method for preparing 2, 3-dimethyl-2H-indazole-6-benzylamine hydrochloride

The invention discloses a method for preparing 2, 3-dimethyl-2H-indazole-6-benzylamine hydrochloride. The method comprises the steps of reacting a glacial acetic acid solution of tert-butyl nitrite and a glacial acetic acid solution of 5-nitro-2-ethylaniline in a first microreactor to generate 3-methyl-6-nitro-1H-indazole; reacting a homogeneous solution formed by mixing the 3-methyl-6-nitro-1H-indazole and a dimethyl sulfoxide solution of methyl iodide and a dimethyl sulfoxide solution of sodium ethoxide in a second microreactor to generate 2,3-dimethyl-6-nitro-2H-indazole; then reacting withmixed liquor formed by stirring a concentrated hydrochloric acid solution of stannous chloride and ethyl alcohol in a third microreactor to generate the 2, 3-dimethyl-2H-indazole-6-benzylamine hydrochloride. The method provided by the invention has the advantages of less side reaction, high yield, simplification of a complicated multi-step synthesis process, low toxicity and pollution, low production cost, good product quality, environment friendliness, energy saving and high efficiency, and is suitable for industrialized application.

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol- 6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4- pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of pyrimidine derivatives. In particular, the method relates to a method of treating cancer by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or a salt or solvate thereof.